RxDoctor Payments Data

Chris Weber, MD

Physical Medicine and Rehabilitation · Branson, MONPI 1891744579

Payments from drug & device makers

$190in general payments, 2019–2025

Across 15 payments — averaging $12.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$72
  • Biodelivery Sciences International, Inc.$23
  • Boston Scientific$20
  • Bioventus LLC$18
  • Abbott$18
  • Pacira Therapeutics, Inc.$13
  • plus $25 from 2 others
$125in research payments, 2019–2025

Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$125

What the payments were for

  • Food & beverage$18598%
  • Education$42%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$190 in reported general payments places this provider in the 50th percentile of 182 physical medicine and rehabilitation providers in Missouri.

See all physical medicine and rehabilitation providers in Missouri

Medicare billing

Part B allowed, 2024
$61,152
Medicare patients
140
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl293$30,744
Buprenorphine46$11,098
Xtampza ErOxycodone Myristate13$8,803
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$7,943
Buprenorphine Hcl192$5,714
Fentanyl46$5,232
Venlafaxine Hcl ErVenlafaxine Hcl12$3,459
Celecoxib119$3,152
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen110$3,051
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen182$2,949
Gabapentin145$2,797
Morphine Sulfate ErMorphine Sulfate63$1,811
Oxycodone Hcl80$1,677
Duloxetine Hcl56$1,402
Pregabalin41$1,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$13$8,80313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 182 physical medicine and rehabilitation providers in Missouri.

Other physical medicine and rehabilitation in Branson

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →